Investigational Drug Versus an Approved Drug in Patients With Rheumatoid Arthritis (0663-072)(COMPLETED)
The purpose of this study is to evaluate the long-term safety of an investigational drug versus an approved drug for the relief of pain in patients with rheumatoid arthritis.
Drug: MK0663, etoricoxib
Drug: Comparator: Diclofenac sodium
|Study Design:||Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
|Official Title:||A Randomized, Double-Blind, Multicenter Study to Evaluate the Tolerability and Effectiveness of Etoricoxib 90 mg q.d. vs. Diclofenac Sodium 75 mg b.i.d. in Patients With Rheumatoid Arthritis|
- Discontinuations due to clinical and laboratory gastrointestinal adverse experiences
|Study Start Date:||February 2003|
|Primary Completion Date:||December 2005 (Final data collection date for primary outcome measure)|
The duration of treatment is 12 months.